Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

Published:2020-04-21 Issue:1 Volume:35 Page:255-258
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Lee Hans C.,Raje Noopur S.,Landgren Ola^ORCID,Upreti Vijay V.,Wang Jin,Avilion Ariel A.,Hu Xuguang,Rasmussen Erik,Ngarmchamnanrith Gataree,Fujii Hisaki,Spencer Andrew

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0834-9.pdf

Reference10 articles.

1. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–8.

2. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–75.

3. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–60.

4. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689–94.

5. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol. 2007;179:7276–86.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma;Journal of Clinical Oncology;2024-08-01

2. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma;Expert Review of Anticancer Therapy;2024-05-26

3. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma;Cell Death Discovery;2024-01-27

4. Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review;Therapeutic Advances in Hematology;2024-01

5. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future;International Journal of Molecular Sciences;2023-10-27